Helicobacter pylori screening: options and challenges

References

• Sugano K, Tack J, Kuipers EJ, et al. Faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015. DOI:10.1136/gutjnl-2015-309252.
   Web of Science ®Google Scholar
• Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–1461.
   PubMed Web of Science ®Google Scholar
• Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10:495–500.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Mégraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV Florence Consensus Report. Gut. 2012;61:646–664.
   PubMed Web of Science ®Google Scholar
• Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–682.
   PubMed Web of Science ®Google Scholar
• Venerito M, Malfertheiner P. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter. 2010;15:239–250.
   PubMed Web of Science ®Google Scholar
• Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–979.
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. Bmj. 2014;348(g3174):1–13.
   Google Scholar
• Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;2:CD004062. Review.
   PubMedGoogle Scholar
• Moayyedi P, Soo S, Deeks JJ, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2011;16(2):CD002096.
   Google Scholar
• Forman D, Sierra MS. The current and projected global burden of gastric cancer (IARC Working Group Reports, No. 8) IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer, International Agency for Research on Cancer, Lyon, France (2014), pp.5–15 Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.ph
   Google Scholar
• Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC Working Group report. Best Pract Res Clin Gastroenterol. 2014;28:1107–1114.
   PubMed Web of Science ®Google Scholar
• Bornschein J, Selgrad M, Warnecke M, et al. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010;55:3124–3131.
   PubMed Web of Science ®Google Scholar
• Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2015. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Venerito M, Malfertheiner P. Preneoplastic conditions in the stomach: always a point of no return?. Dig Dis. 2015;33:5–10.
   PubMed Web of Science ®Google Scholar
• http://globocan.iarc.fr/factsheets/cancers/stomach.asp.
   Google Scholar
• Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–492.
   PubMed Web of Science ®Google Scholar
• Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49:1–8.
   PubMed Web of Science ®Google Scholar
• Cho E, Kang MH, Choi KS, et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev. 2013;14:2533–2540.
   PubMedGoogle Scholar
• Lu YL, Lui LY, Wu Q, et al. Comparison of two cancer screening schemes in a high-risk population. Chin J Oncol. 2012;35:394–397.
   Google Scholar
• Malfertheiner P, Selgrad M. Gastric cancer screening in conjunction with colorectal cancer screening in Europe (GACSE). Clinical Study Protocol, Version. 2013;1.
   Google Scholar
• Leja M, Herrero R, Park JY, et al. Multicentric randomized study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality (Gastric cancer prevention study by predicting atrophic gastritis; GISTAR), In: Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. IARC Helicobacter pylori Working Group. Lyon, France: International Agency for Research on Cancer ( IARC Working Group Reports, No. 8), Ch 4.2., pp. 1474–1153.
   Google Scholar
• Brenner H, Arndt V, Stürmer T, et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer. 2000;88:274–279.
   PubMed Web of Science ®Google Scholar
• Dhillon PK, Farrow DC, Vaughan TL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer. 2001;93:148–152.
   PubMed Web of Science ®Google Scholar
• Bakir T, Can G, Siviloglu C, et al. Gastric cancer and other organ cancer history in the parents of patients with gastric cancer. Eur J Cancer Prev. 2003;12:183–189.
   PubMed Web of Science ®Google Scholar
• Chen MJ, Wu DC, Ko YC, et al Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J Gastroenterol. 2004;99:1250–1257.
   PubMed Web of Science ®Google Scholar
• Foschi R, Lucenteforte E, Bosetti C, et al Family history of cancer and stomach cancer risk. Int J Cancer. 2008;123:1429–1432.
   PubMed Web of Science ®Google Scholar
• Gao Y, Hu N, Han X, et al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer. 2009;9:269.
   PubMed Web of Science ®Google Scholar
• Shin CM, Kim N, Yang HJ, et al Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol. 2010;44:e34–39.
   PubMedGoogle Scholar
• Kwak HW, Choi IJ, Kim CG, et al. Individual having a parent with early-onset gastric cancer may need screening at younger age. World J Gastroenterol. 2015;21:4592–4598.
   PubMed Web of Science ®Google Scholar
• Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.
   PubMed Web of Science ®Google Scholar
• Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol. 2015;110:684–689.
   PubMed Web of Science ®Google Scholar
• Chan FK, To KF, Jc W, et al Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.
   PubMed Web of Science ®Google Scholar
• De Leest HT, Steen KS, Wf L, et al Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter. 2007;12:477–485.
   PubMed Web of Science ®Google Scholar
• Lai KC, Lau CS, Ip WY, et al Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2003;17:799–805.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Tulassay Z, Szczepanski L, et al Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016–1021.
   PubMed Web of Science ®Google Scholar
• Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967–973.
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–535.
   PubMed Web of Science ®Google Scholar
• Song HJ, Kwon JW, Kim N, et al. Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. Gut Liver. 2013;7:182–189.
   PubMed Web of Science ®Google Scholar
• Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015. DOI:10.1136/gutjnl-2014-308588. Epub ahead of print.
   Google Scholar
• Cheng HC, Wang JD, Chen WY, et al. Helicobacter pylori test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: referred to the nationwide reimbursement database. Helicobacter. 2015;20:114–124.
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015. DOI:10.1016/S0140-6736(15)60310-5.
   Web of Science ®Google Scholar
• Fock KM, Talley N, Moayyedi P, et al Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008;23:351–365.
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 2008;47:1077–1083.
   PubMed Web of Science ®Google Scholar
• Gonzalez CA, Jakszyn P, Pera G, et al Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:345–354.
   PubMed Web of Science ®Google Scholar
• Gonzalez CA, Lopez-Carrillo L. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis. Scand J Gastroenterol. 2010;45:6–14.
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. International Workshop on the Histopathology of Gastritis, Houston 1994.
   PubMed Web of Science ®Google Scholar
• Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:650–658.
   PubMedGoogle Scholar
• Dinis-Ribeiro M, Areia M, De Vries AC, et al. European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of Precancerous Conditions and Lesions in the Stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa De Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74–94.
   Google Scholar